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doi:10.1Objective: To determine the impact of bridge-to-transplant ventricular assist device support on survival after car-
diac transplantation.
Methods: From January 1, 1993, to April 30, 2009, a total of 525 cardiac transplants were performed. Ventricular
assist devices were placed as a bridge to transplant in 110 patients. We focused our analysis on the 2 most com-
mon causes of end-stage heart failure requiring transplantation: idiopathic dilated cardiomyopathy (n¼ 201) and
coronary artery disease (n¼ 213). Data including gender, age, date of transplant, cause of heart failure, prior heart
transplant, placement of a ventricular assist device, type of ventricular assist device, and panel-reactive antibody
sensitization were analyzed to derive Kaplan–Meier survival probabilities and multivariable Cox regression
models.
Results: In patients with idiopathic dilated cardiomyopathy who received a ventricular assist device as a bridge
to transplant, survival was decreased at 1 year (P ¼ .008) and 5 years (P ¼ .019), but not at 10 years, posttrans-
plant. In patients with coronary artery disease, the use of a ventricular assist device as a bridge to transplant did
not influence survival at 1, 5, and 10 tears posttransplant. In patients with idiopathic dilated cardiomyopathy
who received a Heartmate I (Thoratec Corp, Pleasanton, Calif) ventricular assist device as a bridge to a cardiac
transplant, elevation in the pretransplant panel-reactive antibody correlated with a decrease in long-term
survival.
Conclusion: In patients with idiopathic dilated cardiomyopathy, placement of a Heartmate I ventricular assist
device as a bridge to a cardiac transplant is associated with an elevation in the pretransplant panel-reactive
antibody and a decrease in 1- and 5-year survivals after cardiac transplantation. (J Thorac Cardiovasc Surg
2010;140:169-73)T
XCardiac transplantation remains the gold standard for the
treatment of end-stage heart failure. The major factor limiting
the number of heart transplants performed in the United
States today is the availability of donor hearts. Ventricular as-
sist devices (VADs) allow for the successful bridging of pa-
tients who otherwise would not be expected to survive long
enough to receive a heart transplant.1-3 Previous studies
have reported equivalent survival at 1, 2, and 5 years in
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The Journal of Thoracic and Cabroader population of heart transplant recipients.4,5 More
recent studies, however, have found that bridge-to-
transplant VADs are associated with an increase in mortality
within 6 months and more than 5 years after cardiac trans-
plantation.6 We examined our experience with the use of
bridge-to-transplant VADs, with particular attention to heart
failure cause, to determine their impact on survival after car-
diac transplantation.MATERIALS AND METHODS
This study was reviewed and approved by the institutional review board
at the University of Utah Health Sciences Center. All patients undergoing
cardiac transplantation from January 1, 1993, to April 30, 2009, in the
Utah Transplant Affiliated Hospitals (UTAH) heart transplant program
were included in the analysis. The UTAH heart transplant program had
its inception in 1985. The start date for this analysis is 1993 because this
was the inception of the VAD program within the UTAH heart transplant
program. Patients undergoing heart–lung transplantation were excluded
from the analysis. Specific data regarding date of transplant, mortality, cause
of death, gender, age, cause of heart failure, prior heart transplant, United
Network for Organ Sharing status, previous cardiac surgery, placement of
a VAD, type of VAD, transfusion of cellular blood products, duration of
VAD support, panel-reactive antibody (PRA) sensitization, use of pretrans-
plant and perioperative plasmapheresis for desensitization in patients with
a PRA more than 90%, immunosuppressive agents, immunosuppressionrdiovascular Surgery c Volume 140, Number 1 169
Abbreviations and Acronyms
CAD ¼ coronary heart disease
CI ¼ confidence interval
HR ¼ hazard ratio
IDC ¼ idiopathic dilated cardiomyopathy
LVAD ¼ left ventricular assist device
PRA ¼ panel-reactive antibody
UTAH ¼ Utah Transplant Affiliated Hospitals
VAD ¼ ventricular assist device
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Xprotocols, incidence and severity of acute cellular and humoral rejection
posttransplant, and incidence of cardiac allograft vasculopathy were col-
lected for each patient. Patients who did and did not receive a VAD as
a bridge to a cardiac transplant were compared with regard to each of the
above listed variables with a 2-sample t test for continuous variables and
a chi-square or Fisher’s exact test, as appropriate, for categoric variables.
These 2 groups were then analyzed using multivariable Cox regression.
Only 3 patients had 2 transplants in the dataset, which was not enough to
introduce lack of independence among the observations. Therefore, there
was no need to account for lack of independence with a shared frailty
Cox regression, which is the Cox regression analog of a mixed-effects linear
regression. On the basis of the limited sample size of this study, multivari-
able Cox regression rather than propensity score matching was used to con-
trol for the potentially confounding variables in the analysis. For this
particular analysis, the use of propensity score matching in the limited
sample size of the study would have required loose matching to maintain
an adequate sample size, leaving several residual confounding variables
in the analysis.
Given that the posttransplant follow-up was measured as a continuous
variable, accurate to a day, rather than a predetermined time interval such
as a year, the Kaplan–Meier approach was used to obtain survival estimates
for specific time points, rather than the actuarial method, which is designed
for data aggregated by time interval.
The data were analyzed to derive Kaplan–Meier survival probabilities
and to fit the multivariable shared frailty Cox regression models. Hazard ra-
tios (HRs), confidence intervals (CIs), and P values were calculated for each
variable. The primary end point of the analysis was the impact of pretrans-
plant VAD support on patient survival after cardiac transplantation. The sec-
ondary end point of the analysis was the impact of pretransplant PRA on
patient survival after cardiac transplantation. Data are reported as the
mean  standard deviation.RESULTS
From January 1, 1993, to April 30, 2009, a total of 525
cardiac transplants were performed in the UTAH heart trans-
plant program. The most common indications for transplan-
tation were ischemic cardiomyopathy as a result of coronary
artery disease (CAD, n¼ 213) and idiopathic dilated cardio-
myopathy (IDC, n ¼ 201) (Table 1). Among the cardiac
transplants, VADs were placed as a bridge to transplant in
110 patients. Among the 110 patients receiving VADs, the
cause of heart failure was CAD (n ¼ 59) or IDC (n ¼ 45)
in 104 patients (Table 1). We therefore focused our analysis
on the patients with a history of CAD and IDC because these
2 subgroups had sufficient numbers of patients with and
without VADs for statistical analysis.170 The Journal of Thoracic and Cardiovascular SurgFor the entire cardiac transplant program, Kaplan–Meier
survival probability at 1, 5, 10, and 15 years posttransplant
was 90%, 77%, 59%, and 44% respectively. In patients
with CAD, the use of a VAD as a bridge to transplant did
not influence survival at 1, 5, and 10 tears posttransplant.
In patients with IDC, the use of a VAD as a bridge to trans-
plant was associated with a decrease in Kaplan–Meier
survival probability at 1 year (84% vs 96%, P ¼ .008)
and 5 years (66% vs 82%, P ¼ .019) posttransplant
(Table 2, Figure 1). Specifically, the use of a Heartmate I
(Thoratec Corp, Pleasanton, Calif) VAD was associated
with a decrease in survival in patients with IDC at 1 year
(HR ¼ 4.33; CI, 1.46–12.90) and 5 years (HR ¼ 2.25; CI,
1.14–4.42) posttransplant. There was no significant differ-
ence in survival, however, for patients with IDC at 10 years
posttransplant when comparing patients with and without
VADs (62% vs 67%, P ¼ .11, Figure 1).
Patients with IDC receiving VADs as a bridge to trans-
plant were more likely to have a PRA greater than 10%
than the precardiac transplant population without VADs.
In patients with IDC who received a VAD as a bridge to
transplant, the pretransplant PRA was elevated to 35% 
40% versus only 5%  14% in the patients without
VADs (P< .001). In addition, among the patients with
IDC, 40% of the patients who received a VAD had a PRA
greater than 10%, compared with only 10% of the patients
without VADs (P< .001). Some 32% of patients with IDC
with a VAD had a PRA greater than 40% (P< .001), and
20% of patients with IDC with a VAD had a PRA greater
than 75% (P< .001).
In both the IDC and CAD groups, the transfusion of cel-
lular blood products, the duration of VAD support, and the
use of pretransplant and perioperative plasmapheresis for de-
sensitization in patients with a PRA greater than 90% did
not affect long-term survival after transplantation. Similarly,
United Network for Organ Sharing status and the incidence
of reoperative cardiac surgery did not affect long-term
survival. The incidence and severity of acute cellular and hu-
moral rejection, immunosuppressive agents, immunosup-
pression protocols, and cardiac allograft vasculopathy did
not differ between those with and without VADs in the
IDC and CAD groups. Finally, although 1- and 5-year sur-
vivals were decreased for patients with VADs in the IDC
group, the incidences of mortality cause (ie, acute rejection,
infection, cardiac allograft vasculopathy, and malignancy)
did not differ between patients with and without VADs.
During the time period analyzed, the predominant bridge-
to-transplant VADs used in the UTAH heart transplant pro-
gram were the Heartmate I and Heartmate II systems. The
Heartmate I system was used exclusively until 2004, when
the Heartmate II system also began to be placed as
a bridge-to-transplant device. An interesting finding with re-
gard to these 2 VAD systems is that PRA elevation greater
than 10% was seen only in those patients who receivedery c July 2010
TABLE 1. Patient characteristics
CAD (n ¼ 213)
VAD support
IDC (n ¼ 201)
VAD support
Yes (n ¼ 59) No (n ¼ 154) P value Yes (n ¼ 45) No (n ¼ 156) P value
Age at transplant, y mean  SD 54  8 54  9 .88 42  17 43  16 .91
Female, n (%) 5 (8) 10 (6) .61 9 (20) 46 (29) .21
PRA>10% (%) 16 (27) 12 (8) .006 18 (40) 15 (10) <.001
HeartMate I (Thoratec Corp,
Pleasanton, Calif) (%)
57 (97) 0 (0) – 41 (91) 0 (0) –
HeartMate II (%) 2 (3) 0 (0) 4 (9) 0 (0)
CAD, Coronary artery disease; IDC, idiopathic dilated cardiomyopathy; VAD, ventricular assist device; SD, standard deviation; PRA, panel-reactive antibody. Characteristics of
patients with CAD or IDC with and without bridge to transplants in the UTAH heart transplant program from 1993 to 2009.
Bull et al Cardiothoracic Transplantationa Heartmate I device. Patients who received a Heartmate II
device did not have an elevation in their measured PRA.
Elevation in the pretransplant PRA was correlated with a de-
crease in survival in patients with IDC at 1 year (HR¼ 4.42;
CI, 1.11–17.67, P ¼ .035) and 5 years (HR ¼ 1.91; CI,
0.82–4.46, P ¼ .04) after cardiac transplantation.T
XDISCUSSION
To our knowledge, this is the first report in the literature
examining the impact of VADs as a bridge to transplant
on long-term (ie,10 years) survival after cardiac transplan-
tation. Conducting such a study has only recently become
possible, because VADs were not widely adopted for
bridging to cardiac transplantation until the 1990s.1–5
Previous reports have not found a difference in survival in
patients with and without VADs at 1, 2, and 5 years
posttransplant.4,5 These previous reports, however,
grouped their patients with bridge-to-transplant VADs,
regardless of heart failure cause, and compared them with
the general population of heart transplant recipients.4,5
More recent studies have found that bridge-to-transplant
VADs are associated with an increase in mortality withinTABLE 2. Kaplan–Meier survival probabilities in patients with
idiopathic dilated cardiomyopathy by ventricular assist device support
IDC (n ¼ 201) Entire
transplant
program
(N ¼ 525)Follow-up
VAD support
Yes (n ¼ 45) No (n ¼ 156)
1 y 0.84 (0.70–0.92)
n ¼ 38
0.96 (0.92–0.98)
n ¼ 148
0.90 (0.88–0.93)
n ¼ 472
5 y 0.66 (0.48–0.79)
n ¼ 18
0.82 (0.74–0.87)
n ¼ 90
0.77 (0.73–0.81)
n ¼ 284
10 y 0.62 (0.43–0.76)
n ¼ 8
0.67 (0.57–0.75)
n ¼ 43
0.59 (0.53–0.64)
n ¼ 121
15 y 0.53 (0.30–0.72)
n ¼ 1
0.50 (0.36–0.63)
n ¼ 9
0.44 (0.37–0.52)
n ¼ 21
IDC, Idiopathic dilated cardiomyopathy; VAD, ventricular assist device. Survival
probabilities and 95% CIs for the entire transplant program and in patients with
IDC by VAD support at 1, 5, 10, and 15 years posttransplant.
The Journal of Thoracic and Ca6 months and beyond 5 years after cardiac transplantation.6
An important distinction between these prior reports and our
study is that we have sufficient numbers of patients with and
without VADs in the 2 most common groups presenting for
transplantation, IDC and ischemic cardiomyopathy, to allow
for a more detailed analysis of the direct impact of VAD sup-
port in each group. In patients with IDC, the decrease in sur-
vival among the patients receiving VADs became manifest
at 1 year posttransplant and continued through 5 years post-
transplant. In patients with ischemic cardiomyopathy, the
use of VADs as a bridge to transplant did not affect survival
after cardiac transplantation. These differences in outcomes
based on heart failure cause may explain why prior reports,
which have not taken heart failure cause into account, have
not found a difference in survival between patients with and
without VADs at 1, 2, or 5 years posttransplant.
Among all the potential variables that were examined in
this study, the only important contributors to the decrease
in posttransplant survival in the patients with IDC who re-
ceived a VAD as a bridge to cardiac transplantation were
the presence of a PRA greater than 10% and the use of
a Heartmate I device. Previous reports have suggested that
the need for transfusion of cellular blood products at the
time of VAD placement increases the incidence of humoral
sensitization in left ventricular assist device (LVAD) recipi-
ents.7–9 Our group has previously reported, however, that
avoidance of perioperative leukocyte-filtered cellular trans-
fusions does not decrease the incidence or degree of human
leukocyte antigen sensitization in LVAD recipients.10,11 In
this study, we found no correlation between the incidence
or extent of blood transfusion and the long-term survival in
patients with and without VADs posttransplant. We also
found that the duration of VAD support before transplant
did not affect long-term survival after transplantation. Fur-
ther, the use of a VAD as a bridge to transplant did not change
the incidence or severity of acute cellular or humoral rejec-
tion or the development of cardiac allograft vasculopathy af-
ter cardiac transplantation. Although 1- and 5-year survivals
were decreased for patients with VADs in the IDC group, the
incidences of mortality cause (ie, acute rejection, infection,rdiovascular Surgery c Volume 140, Number 1 171
FIGURE 1. Comparison of long-term survival after cardiac transplantation in IDC patients with a VAD as bridge to transplant and IDC patients who did not
receive a VAD as bridge to transplant. IDC, Idiopathic dilated cardiomyopathy; VAD, ventricular assist device.
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Xcardiac allograft vasculopathy, and malignancy) did not dif-
fer between patients with and without VADs.
The development of immunoglobulin-G antibodies to hu-
man leukocyte antigen class I and II antigens by PRA
screening occurs in up to 60% of patients after placement
of an LVAD.4 Humoral sensitization after placement of an
LVAD is defined as the development of an elevation in
PRA greater than 10%.12 The degree of sensitization has
been reported to differ by LVAD device type,12 occurring
most frequently in patients receiving Thoratec, Heartmate
I, and Novacor (World Heart Inc, Salt Lake City, Utah) de-
vices.12 Despite the increased incidence of humoral sensiti-
zation in patients with LVADs, the incidence of acute and
chronic rejection in LVAD recipients is not increased post-
transplant.4,12
The type of VAD placed as a bridge to transplant does not
seem to influence the incidence of posttransplant rejection or
survival at 1 year posttransplant, but it does influence sur-
vival at 5 years posttransplant.13 In addition, the rate and se-
verity of posttransplant rejection has been noted to be higher
in LVAD recipients with continuous-flow devices than in
patients with pulsatile devices.14 This is particularly interest-
ing given the finding in our series that the implantation of the
Heartmate II device was not associated with an increase in
the PRA. The interaction between blood elements and the
biomaterials of the VAD, specifically the textured chamber
surface found in the Heartmate I, may be the mechanism re-
sponsible for the increased immunologic and inflammatory
response seen in this group of patients.15 The textured sur-
face of the Heartmate I device results in the formation of
a pseudointima that contains an abundance of T cells, mac-
rophages, and monocytes as a result of the continuous172 The Journal of Thoracic and Cardiovascular Surgdynamic interaction of the blood with the device.15 Aberrant
T-cell activation, defective T-cell proliferation, and poly-
clonal B-cell hyperreactivity with CD40 ligand interaction
have all been reported in association with use of the Heart-
mate I device.15-17
Next-generation axial-flow devices, such as the Heart-
mate II, have been hypothesized to lower the immunologic
and inflammatory response seen after LVAD implantation.
In this study, our finding that the Heartmate II is not associ-
ated with an increase in the PRA after implantation supports
this hypothesis. Possible reasons for the decreased immune
response seen with the Heartmate II device are the decrease
in the textured surface area and the absence of biologic
chamber valves compared with the Heartmate I device. In
the Heartmate II device, the textured surfaces are found
only along the course of the inflow cannula of the device.
Other investigators have also noted that patients receiving
an axial-flow VAD do not become sensitized after device
implantation.18 A recent study comparing sensitization rates
between axial flow devices and Heartmate I devices found
that the Heartmate I was associated with a significantly in-
creased incidence of allosensitization compared with axial
flow devices.19
Taken in aggregate, these findings suggest that an as yet
unidentified alteration of the immune response is activated
in some patients by the placement of a Heartmate I VAD.
This alteration of the immune response seems to manifest
itself initially as an elevation in the pretransplant PRA. As
stated above, the placement of a Heartmate I device has
been associated with aberrant T-cell activation, defective
T-cell proliferation, and polyclonal B-cell hyperreactivity
with CD40 ligand interaction.15-17 Whether there is a directery c July 2010
Bull et al Cardiothoracic Transplantationcausal relationship between an increase in the pretransplant
PRA and these immune system alterations is unknown at
the present time. Our study suggests, however, that this
alteration of the immune response may persist and have
implications for survival in patients with IDC after cardiac
transplantation. The major limitation in the analysis of this
study is the relative paucity of information regarding the
specific immune system alterations that are present in these
patients before and after cardiac transplantation. As
a result, the significance of an increase in the pretransplant
PRA of more than 10% in an individual patient remains
unclear, particularly with regard to what intervention
should be made, if any, when this finding is encountered
clinically. At the present time, we are actively trying to
identify the specific immune mediators that may
responsible for the increase in PRA and decrease in
survival after cardiac transplantation in patients with IDC
who received a Heartmate I as a bridge to a cardiac
transplant. The ongoing transition to the use of continuous
axial-flow assist devices for bridge to transplant may have
previously unrecognized beneficial effects with regard to
long-term survival after cardiac transplantation.T
XCONCLUSIONS
There are several important limitations to this study that
should be noted. This is a retrospective analysis from a single
regional heart transplant center of patients who were not ran-
domized as to whether they received a VAD or proceeded
directly to a cardiac transplant. As a result, important vari-
ables, including patient functional status and technical as-
pects of the operative procedures, that might influence
whether a patient received a VAD and, in turn, might impact
long-term survival, may not be included in this analysis.
Given the retrospective nature of the analysis, the reasons
for the observed differences in survival between the VAD
and non-VAD subgroups among the patients with IDC
cannot be directly identified. We plan additional prospective
studies in the future to better elucidate the factors determin-
ing long-term survival in these patients after cardiac trans-
plantation.References
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